3 unchanged sentences
In January 2019, our Board of Directors established the current $10 million repurchase program to replace the prior authorizations for repurchases of our outstanding common stock.
−Removed: The following table summarizes the activity, by month, during the three months ended September 30, 2021:
+Added: The following table summarizes the activity, by month, during the three months ended March 31, 2022:
Period Total Number of
7 unchanged sentences
Purchased Under
−Removed: July 39,264 $ 3.28 $ 5,273,299
−Removed: August 24,424 2.98 5,200,518
−Removed: September 12,720 (1)
+Added: January 46,642 $ 3.96 $ 4,595,056
+Added: February 37,910 3.42 4,465,495
+Added: March 89,597 (1)
2.81 4,213,590
+Added: Total 174,149
(1) Of this amount, 50,874 shares were repurchased directly through private purchases at the then-current fair market value of common stock.
−Removed: 10.1* Fourth Amendment to Revolving Credit Note and Fifth Amendment to Revolving Credit Loan Agreement, dated as of October 28, 2021, by and between Cumberland Pharmaceuticals Inc.
+Added: 10.1* Employment Agreement dated March 7, 2022, effective as of January 1, 2022, by and between A.J.
+Added: Kazimi and Cumberland Pharmaceuticals Inc.
+Added: (incorporated by reference to Exhibit 10.11 of the Company’s Annual Report on Form 10-K, File No.
+Added: 001-33637, filed with the Securities and Exchange Commission on March 11, 2022).
+Added: 10.2* Employment Agreement dated March 7, 2022, effective as of January 1, 2022, by and between Leo B.
+Added: Pavliv and Cumberland Pharmaceuticals Inc.
+Added: (incorporated by reference to Exhibit 10.13 of the Company’s Annual Report on Form 10-K, File No.
+Added: 001-33637, filed with the Securities and Exchange Commission on March 11, 2022).
+Added: 10.3* Employment Agreement dated March 7, 2022, effective as of January 1, 2022, by and between John M.
+Added: Hamm and Cumberland Pharmaceuticals Inc.
+Added: (incorporated by reference to Exhibit 10.14 of the Company’s Annual Report on Form 10-K, File No.
+Added: 001-33637, filed with the Securities and Exchange Commission on March 11, 2022).
+Added: 10.4* Employment Agreement dated March 7, 2022, effective as of January 1, 2022, by and between James L.
+Added: Herman and Cumberland Pharmaceuticals Inc.
+Added: (incorporated by reference to Exhibit 10.15 of the Company’s Annual Report on Form 10-K, File No.
+Added: 001-33637, filed with the Securities and Exchange Commission on March 11, 2022).
+Added: 10.5* Seventh Amendment to Revolving Credit Loan Agreement , dated as of March 31 , 202 2 , by and between Cumberland Pharmaceuticals Inc.
and Pinnacle Bank.
14 unchanged sentences
Cumberland Pharmaceuticals Inc.
−Removed: November 12, 2021 By:
+Added: May 13, 2022 By:
/s/ John Hamm
1 unchanged sentence
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.